Lip, Oral Cavity and Pharynx, Phase II

Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab in Patients With Selected Resectable Tumors

Volunteers
Health Professionals

What is the purpose of this trial?

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

Trial with
IO Biotech
Ages
18 years and older
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Anna Wu

anna.wu@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Barbara Burtness, MD
Anthony N. Brady Professor of Medicine (Medical Oncology); Chief Translational Research Officer, Yale Cancer Center; Chief, Head and Neck Cancers/Sarcoma; Co-Leader, Developmental Therapeutics, Yale Cancer Center; Associate Cancer Center Director for Translational Research, Yale Cancer Center

Sub-Investigators

Last Updated
04/10/2024
Study HIC
#2000035502